| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.23 | 9e-07 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.16 | 0.0002 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.0003 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.17 | 0.0004 |
| mRNA | PF-573228 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0006 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.0006 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.19 | 0.0009 |
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | 0.097 | 0.001 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.001 |
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | 0.16 | 0.001 |